PlasmaGen secures ₹150 cr to expand into global markets

Biopharmaceutical company PlasmaGen Biosciences raised ₹150 crore in a new round of equity financing, valuing the firm at more than ₹1,500 crore.

- Rwit Ghosh

ViNS Bioproducts, a specialty biopharma company, picked up a minority equity stake in PlasmaGen and led the round with participation from existing investors and other pharma companies and family offices.

PlasmaGen will use the new funds to take its business international. The company has identified distribution partners in “key” export markets.

Back home, the company plans to double down on its presence with its current portfolio of plasma-derived therapeutics. The company’s key products include albumin, intravenous immunoglobulin, rabies immunoglobulin, hepatitis B immunoglobulin, and RhD immunoglobulin (anti-D) which it distributes to private hospitals and state hospitals in India.